Fitness6 months ago
Neurona’s Focal Epilepsy Cell Therapy NRTX-1001 Garners FDA RMAT Designation
Neurona Therapeutics’ NRTX-1001, an investigational allogeneic regenerative neural cell therapy intended to treat drug-resistant mesial temporal lobe epilepsy (MTLE), has been granted regenerative medicine advanced therapy (RMAT)...
